

Stanford



Nam Quoc Bui

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

875 Blake Wilbur Dr
Stanford, CA 94305

Tel (650) 724-5214 **Fax** (650) 724-3556

Bio

BIO

Dr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.

CLINICAL FOCUS

- Medical Oncology
- Sarcoma
- Phase 1 Trials

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (ASCO) (2014 - present)
- Associate Member, Stanford Cancer Institute (2018 - present)
- Member, Connective Tissue Oncology Society (CTOS) (2017 - present)

PROFESSIONAL EDUCATION

- Residency: Stanford University Internal Medicine Residency (2014) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2017)
- Fellowship: UCSD Hematology and Oncology Training (2017) CA
- Board Certification: Hematology, American Board of Internal Medicine (2017)
- Medical Education: University of Texas Southwestern Medical School Registrar (2011) TX

- Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
- B.S., Stanford University , Computer Science (2007)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- A Study of AL102 in Patients With Progressing Desmoid Tumors, Recruiting
- Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors, Recruiting
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma, Recruiting
- A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma, Not Recruiting
- A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer, Not Recruiting
- A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors, Not Recruiting
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer, Not Recruiting
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF), Not Recruiting
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations, Not Recruiting
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS), Not Recruiting

Publications

PUBLICATIONS

- **The interaction of SWI/SNF with the ribosome regulates translation and confers sensitivity to translation pathway inhibitors in cancers with complex perturbations.** *Cancer research*
Ulicna, L., Kimmey, S. C., Weber, C. M., Allard, G. M., Wang, A., Bui, N. Q., Bendall, S. C., Crabtree, G. R., Bean, G. R., Van Rechem, C.
2022
- **Current management and recent progress in desmoid tumors.** *Cancer treatment and research communications*
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ghanouni, P., Ganjoo, K. N.
2022; 31: 100562
- **WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.** *JCI insight*
Ponce, R. K., Thomas, N. J., Bui, N. Q., Kondo, T., Okimoto, R. A.
2022; 7 (6)
- **Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.** *PloS one*
Przybyl, J., Spans, L., Ganjoo, K., Bui, N., Mohler, D., Norton, J., Poultsides, G., Debiec-Rychter, M., van de Rijn, M.
2022; 17 (1): e0262272
- **Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.** *Cancers*
Testa, S., Bui, N. Q., Wang, D. S., Louie, J. D., Sze, D. Y., Ganjoo, K. N.
2022; 14 (2)
- **Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.** *Case reports in oncology*
Lanman, T., Hayden Gephart, M., Bui, N., Toland, A., Nagpal, S.
2021; 14 (3): 1841-1846
- **PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM**
Bhadri, V., Subbiah, V., Strauss, J., Chawla, S., Bui, N., Kwatra, V., Weiss, M., Batty, K., Zakharian, M., Oneto, J., Srinivasan, S., Yee, N., Wilson, et al

BMJ PUBLISHING GROUP.2021: A395

- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma.** *Journal of vascular and interventional radiology : JVIR*
Doshi, A., Zhou, M., Bui, N., Wang, D. S., Ganjoo, K., Hwang, G. L.
2021
- **Phase I trial of SQ3370 in solid tumors.**
Guminski, A., Wang, D., Bui, N., Bhadri, V., De Silva, M., Steffner, R., Yee, N. A., Srinivasan, S., Oneto, J., Saville, M., Subbiah, V.
AMER ASSOC CANCER RESEARCH.2021
- **Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Hirbe, A. C., Luo, J., Oppelt, P., Weiss, M. C., Eulo, V., Toeniskoetter, J., Haarberg, S., Abaricia, S., Ruff, T., Bomalaski, J. S., Johnston, A., Kuo, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.**
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M., Seetharam, M., Boikos, S., Bui, N., Chen, J., Close, J., Cote, G., Thaker, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.** *NPJ genomic medicine*
Tolwani, A., Matusiak, M., Bui, N., Forgo, E., Varma, S., Baratto, L., Iagaru, A., Lazar, A. J., van de Rijn, M., Przybyl, J.
2021; 6 (1): 30
- **Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib.** *Case reports in oncology*
Testa, S., Million, L., Longacre, T., Bui, N.
2021; 14 (2): 812-819
- **Evolving role of entrectinib in treatment of NTRK-positive tumors.** *Future oncology (London, England)*
Chawla, N., Bui, N. Q., Seetharam, M.
2021
- **A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma**
Lanman, T., Hayden, M., Bui, N., Nagpal, S.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma.** *JAMA network open*
Brewster, R., Purington, N., Henry, S., Wood, D., Ganjoo, K., Bui, N.
2021; 4 (3): e210845
- **Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.** *Case reports in oncology*
Zhou, M., Bui, N., Lohman, M., van de Rjin, M., Hwang, G., Ganjoo, K.
2021; 14 (1): 459-65
- **Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.** *American journal of clinical oncology*
Yurkiewicz, I. R., Zhou, M., Ganjoo, K. N., Charville, G. W., Bolleddu, S., Lohman, M., Bui, N.
2021
- **A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.** *Current oncology (Toronto, Ont.)*
Testa, S., Hu, B. D., Saadeh, N. L., Pribnow, A., Spunt, S. L., Charville, G. W., Bui, N. Q., Ganjoo, K. N.
2021; 28 (6): 5304-5317
- **Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review.** *Surgical oncology*
Zhou, M., Javadi, C., Charville, G. W., Bui, N. Q., Harris, E. J., Poultides, G. A., Norton, J. A., Visser, B., Lee, B., Dua, M. M., Ganjoo, K. N.

2021; 39: 101670

- **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review** *IMMUNOTHERAPY*
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H., Ganjoo, K.
2020; 12 (18): 1303–12
- **SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS**
Bhadri, V., Bui, N., Guminski, A., Oneto, J., Murthy, R., Sankhala, K., Saville, M., Srinivasan, S., Steffner, R., Subbiah, V., Wang, D., Yee, N.
BMJ PUBLISHING GROUP.2020: A253–A254
- **NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.**
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M., Boikos, S., Bui, N., Chen, J., Close, J., Seetharam, M., Thaker, P. H., Schwartz, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*
Chen, J. W., Kunder, C. A., Bui, N. n., Zehnder, J. L., Costa, H. A., Stehr, H. n.
2020; 25: 31–42
- **Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria**
Chen, J. W., Kunder, C. A., Bui, N., Zehnder, J. L., Costa, H. A., Stehr, H., Altman, R. B., Dunker, A. K., Hunter, L., Ritchie, M. D., Murray, T., Klein, T. E.
WORLD SCIENTIFIC PUBL CO PTE LTD.2020: 31-42
- **Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid.** *JAAD case reports*
Tabata, M. M., Novoa, R. A., Bui, N. Q., Zaba, L. C.
2020; 6 (5): 447–49
- **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.** *Immunotherapy*
Zhou, M. n., Bui, N. n., Bolleddu, S. n., Lohman, M. n., Becker, H. C., Ganjoo, K. n.
2020
- **Dose escalation of tinostamustine in patients with advanced solid tumors**
Mita, A., Loeffler, M., Bui, N., Mehrling, T., Rimmel, B. J., Natale, R. B., Kummar, S.
AMER ASSOC CANCER RESEARCH.2019
- **Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).**
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.
AMER SOC CLINICAL ONCOLOGY.2019
- **A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.
AMER SOC CLINICAL ONCOLOGY.2019
- **Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers** *NATURE COMMUNICATIONS*
Ando, M., Saito, Y., Xu, G., Bui, N. Q., Medetgul-Ernar, K., Pu, M., Fisch, K., Ren, S., Sakai, A., Fukusumi, T., Liu, C., Haft, S., Pang, et al
2019; 10
- **Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies** *MOLECULAR CANCER THERAPEUTICS*
Shatsky, R., Parker, B. A., Bui, N. Q., Heisten, T., Schwab, R. B., Boles, S. G., Kurzrock, R.
2019; 18 (5): 1001–11
- **Contemporary management of metastatic soft tissue sarcoma.** *Current problems in cancer*
Bui, N. Q., Wang, D. S., Hiniker, S. M.
2019
- **Editorial.** *Current problems in cancer*
Bui, N. n.
2019; 43 (4): 249

- **A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.** *Clinical sarcoma research*
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.
2019; 9: 12
- **Reviewing the role of healthy volunteer studies in drug development.** *Journal of translational medicine*
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S.
2018; 16 (1): 336
- **Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation.** *Molecular cancer therapeutics*
Bui, N., Huang, J. K., Bojorquez-Gomez, A., Licon, K., Sanchez, K. S., Tang, S. N., Beckett, A. N., Wang, T., Zhang, W., Shen, J. P., Kreisberg, J. F., Ideker, T.
2018
- **A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.** *Rare tumors*
Bui, N. n., Kamat, N. n., Ravi, V. n., Chawla, S. n., Lohman, M. n., Ganjoo, K. N.
2018; 10: 2036361318771771
- **Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology** *MOLECULAR CANCER THERAPEUTICS*
Husain, H., Nykin, D., Nam Bui, N., Quan, D., Gomez, G., Woodward, B., Venkatapathy, S., Duttagupta, R., Fung, E., Lippman, S. M., Kurzrock, R.
2017; 16 (5): 948-955
- **Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.** *JCO clinical cancer informatics*
Bui, N., Henry, S., Wood, D., Wakelee, H. A., Neal, J. W.
2017; 2017
- **Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer** *MOLECULAR CANCER THERAPEUTICS*
Husain, H., Scur, M., Murtuza, A., Bui, N., Woodward, B., Kurzrock, R.
2017; 16 (2): 265-272
- **Molecular insights into desmoid tumors.** *Oncotarget*
Bui, N. n., Kummar, S. n.
2017; 8 (53): 90608-9
- **Evolution of early phase clinical trials in oncology.** *Journal of molecular medicine (Berlin, Germany)*
Bui, N. Q., Kummar, S. n.
2017
- **Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Bui, N., Woodward, B., Johnson, A., Husain, H.
2016; 17 (5)
- **Reactivation of hepatitis B virus after withdrawal of erlotinib** *CURRENT ONCOLOGY*
Bui, N., Wong-Sefidan, I.
2015; 22 (6): 430-432
- **Dorsal aesthetic lines in rhinoplasty: a quantitative outcome-based assessment of the component dorsal reduction technique.** *Plastic and reconstructive surgery*
Mojallal, A., Ouyang, D., Saint-Cyr, M., Bui, N., Brown, S. A., Rohrich, R. J.
2011; 128 (1): 280-288